BioAlliance Pharma SA (Euronext Paris - BIO), a Company dedicated to the development of orphan oncology products and supportive care products, today announced funding of almost €9 million from bpifrance through a Strategic Industrial Innovation (ISI) program.
An amount of €4.3 million will be allocated directly to BioAlliance Pharma to accelerate the industrial development of Livatag®.
This grant supports the launch of NICE (Nano Innovation for Cancer), the first consortium of nanomedicine stakeholders in France focused on aspects of characterization and industrialization of processes specific to nanodrugs. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France.
Consisting of five public and private partners and led by BioAlliance Pharma, the NICE consortium includes partners with deep expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.
Developed by BioAlliance Pharma, Livatag®, a doxorubicin nanoparticle currently in phase III trial for the treatment of primary liver cancer, will fully benefit from this platform of expertise and the grant awarded by bpifrance will help accelerate the product’s development, especially in the industrial process.
In addition to BioAlliance Pharma, the consortium includes Nanobiotix, developer of NBTXR3, a potentiator of radiation therapy in the local treatment of cancer; CEA-Leti, developer of the Lipidots® platform that uses lipid nanoparticles; DBI, a company specializing in the production of nanomedicine pharmaceutical products and Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specializing in nanoparticle research.